FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and represents a pharmaceutical combination for treating in pain conditions in the form of a solid dosage form for oral administration, characterised by the fact that it contains Mirtazapine 5 mg - 50 mg

The subject invention describes a method of use of Ropinirole TM to alleviate and control menopausal symptoms in women and in particular hot flashes. The invention describes the use of Ropinirole as a dopamine agonist with affinity for the dopamine D2 D3 or D4 receptors. Ropinirole may also be used to treat menopausal symptoms in cojunction with TizanidineTM to further reduce the effects menopausal symptoms by providing a sedative and muscle relaxant effect which aids in sleep. The combination o...

A pharmaceutical composition in liquid dosage form which contains a tizanidine hydrocloride aqueous solution suitable for parenteral, intranasal and oral administration.

A pharmaceutical composition in liquid dosage form which contains a tizanidine hydrocloride aqueous solution suitable for parenteral intranasal and oral administration.

A method of treating the symptoms of spasticity comprises implanting a reservoir-based drug delivery composition into a subject to systemically deliver a therapeutically effective amount of tizanidine to the subject for a long period of time (e.g., one month or one year). The drug delivery composition may include a rate-controlling excipient (e.g., an elastomeric polymer) defining a reservoir containing at least one discrete solid dosage form (e.g., one or more pellets), which includes tizanidin...

A method of treating the symptoms of spasticity comprises implanting a reservoir-based drug delivery composition into a subject to systemically deliver a therapeutically effective amount of tizanidine to the subject for a long period of time (e.g. one month or one year). The drug delivery composition may include a rate-controlling excipient (e.g. an elastomeric polymer) defining a reservoir containing at least one discrete solid dosage form (e.g. one or more pellets) which includes tizanidine fr...

An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.

An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.

The subject invention describes a method of use of Ropinirole TM to alleviate and control menopausal symptoms in women and in particular hot flashes. The invention describes the use of Ropinirole as a dopamine agonist with affinity for the dopamine D2 D3 or D4 receptors. Ropinirole may also be used to treat menopausal symptoms in cojunction with Tizanidine TM to further reduce the effects menopausal symptoms by providing a sedative and muscle relaxant effect which aids in sleep. The combination ...

The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient.